SG11201806140SA - Stable liquid gonadotropin formulation - Google Patents

Stable liquid gonadotropin formulation

Info

Publication number: SG11201806140SA
Authority: SG; Singapore
Prior art keywords: international; pct; formulation; english; february
Prior art date: 2016-02-24

Application number

SG11201806140SA

Other languages

English (en)

Inventor

Helen Ulrika Sjögren

Charlotte Højer-Pedersen

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-24

Filing date

2017-02-24

Publication date

2018-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201806140S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-02-24 Application filed by Ferring Bv filed Critical Ferring Bv

2018-08-30 Publication of SG11201806140SA publication Critical patent/SG11201806140SA/en

Links

102000006771 Gonadotropins Human genes 0.000 title abstract 4
108010086677 Gonadotropins Proteins 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 4
239000002622 gonadotropin Substances 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
239000007788 liquid Substances 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
230000006641 stabilisation Effects 0.000 abstract 2
238000011105 stabilization Methods 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
229940094892 gonadotropins Drugs 0.000 abstract 1
239000012669 liquid formulation Substances 0.000 abstract 1
229930182817 methionine Natural products 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

SG11201806140SA 2016-02-24 2017-02-24 Stable liquid gonadotropin formulation SG11201806140SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1603280.7A GB201603280D0 (en)	2016-02-24	2016-02-24	Stable liquid gonadotropin formulation
PCT/EP2017/054325 WO2017144659A1 (en)	2016-02-24	2017-02-24	Stable liquid gonadotropin formulation

Publications (1)

Publication Number	Publication Date
SG11201806140SA true SG11201806140SA (en)	2018-08-30

Family

ID=55806922

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201806140SA SG11201806140SA (en)	2016-02-24	2017-02-24	Stable liquid gonadotropin formulation

Country Status (36)

Country	Link
US (4)	US10792334B2 (sr)
EP (3)	EP4257149A3 (sr)
JP (3)	JP6932710B2 (sr)
KR (1)	KR102756413B1 (sr)
CN (2)	CN113398250B (sr)
AR (1)	AR107782A1 (sr)
AU (2)	AU2017222292B2 (sr)
BR (1)	BR112018015166A2 (sr)
CA (1)	CA3012759A1 (sr)
CL (1)	CL2018001984A1 (sr)
CO (1)	CO2018007810A2 (sr)
DK (2)	DK3791860T5 (sr)
EA (1)	EA036383B1 (sr)
ES (2)	ES2862193T3 (sr)
FI (1)	FI3791860T3 (sr)
GB (1)	GB201603280D0 (sr)
HR (2)	HRP20210367T1 (sr)
HU (2)	HUE064432T2 (sr)
IL (1)	IL260626B2 (sr)
JO (1)	JOP20170046B1 (sr)
LT (2)	LT3419595T (sr)
MA (2)	MA43686B1 (sr)
MD (2)	MD3419595T2 (sr)
MX (1)	MX381709B (sr)
MY (1)	MY193138A (sr)
PH (1)	PH12018501688B1 (sr)
PL (2)	PL3419595T3 (sr)
PT (2)	PT3791860T (sr)
RS (2)	RS61604B1 (sr)
SG (1)	SG11201806140SA (sr)
SI (2)	SI3791860T1 (sr)
TN (1)	TN2018000284A1 (sr)
TW (1)	TWI755377B (sr)
UA (1)	UA123107C2 (sr)
WO (1)	WO2017144659A1 (sr)
ZA (1)	ZA201804944B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201603280D0 (en)	2016-02-24	2016-04-13	Ferring Bv	Stable liquid gonadotropin formulation
US20190262314A1 (en) *	2018-02-26	2019-08-29	Slayback Pharma Llc	Ready-to-use dexmedetomidine compositions
WO2020071912A1 (en) *	2018-10-02	2020-04-09	Innocore Technologies B.V.	Extended release formulations of human chorionic gonadotropin (hcg)
CN114404575A (zh) *	2020-12-07	2022-04-29	苏州智核生物医药科技有限公司	一种重组人促甲状腺素注射液
WO2022197963A1 (en) *	2021-03-19	2022-09-22	Pfizer Inc.	Long-acting growth hormone compositions
CN118209739A (zh) *	2024-03-19	2024-06-18	厦门宝太和瑞生物技术有限公司	促黄体生成素检测试剂盒
KR102821987B1 (ko) *	2024-10-24	2025-06-26	에이디텍 주식회사	베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0803832A3 (en)	1996-02-28	2000-05-31	Hitachi, Ltd.	Card holder-type balance display
IL122732A0 (en) *	1997-01-15	1998-08-16	Akzo Nobel Nv	Liquid gonadotropin-containing formulation its preparation and a device containing same
IL140984A0 (en) *	1998-07-23	2002-02-10	Lilly Co Eli	Fsh and fsh variant formulations, products and methods
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
KR101105871B1 (ko) *	2005-09-27	2012-01-16	주식회사 엘지생명과학	인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en)	2007-01-11	2007-02-21	Insense Ltd	The Stabilisation Of Proteins
BRPI0818324B8 (pt)	2007-11-01	2021-05-25	Merck Serono Sa	formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
NZ586588A (en)	2008-02-08	2012-10-26	Biogenerix Ag	Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
TWI488640B (zh)	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
KR101668502B1 (ko)	2008-11-04	2016-10-21	아스카 세이야쿠 가부시키가이샤	난포자극호르몬 함유 수성 조성물
RU2553375C2 (ru) *	2010-02-12	2015-06-10	Интас Биофармасьютикалс Лимитед	Жидкий состав фолликулостимулирующего гормона
WO2011108010A2 (en)	2010-03-05	2011-09-09	Intas Biopharmaceuticals Limited	A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) *	2010-07-30	2012-02-15	Ferring B.V.	Stabilization of gonadotropins
AP2016009159A0 (en) *	2013-11-12	2016-04-30	Cadila Healthcare Ltd	Formulation for gonadotropins
GB201603280D0 (en) *	2016-02-24	2016-04-13	Ferring Bv	Stable liquid gonadotropin formulation

2016
- 2016-02-24 GB GBGB1603280.7A patent/GB201603280D0/en not_active Ceased
2017
- 2017-02-19 JO JOP/2017/0046A patent/JOP20170046B1/ar active
- 2017-02-23 TW TW106106132A patent/TWI755377B/zh active
- 2017-02-24 SI SI201731448T patent/SI3791860T1/sl unknown
- 2017-02-24 PH PH1/2018/501688A patent/PH12018501688B1/en unknown
- 2017-02-24 CA CA3012759A patent/CA3012759A1/en active Pending
- 2017-02-24 EP EP23194814.2A patent/EP4257149A3/en not_active Withdrawn
- 2017-02-24 JP JP2018544561A patent/JP6932710B2/ja active Active
- 2017-02-24 ES ES17707527T patent/ES2862193T3/es active Active
- 2017-02-24 MA MA43686A patent/MA43686B1/fr unknown
- 2017-02-24 SG SG11201806140SA patent/SG11201806140SA/en unknown
- 2017-02-24 DK DK20202758.7T patent/DK3791860T5/da active
- 2017-02-24 EA EA201891905A patent/EA036383B1/ru not_active IP Right Cessation
- 2017-02-24 MY MYPI2018001301A patent/MY193138A/en unknown
- 2017-02-24 PT PT202027587T patent/PT3791860T/pt unknown
- 2017-02-24 PT PT177075272T patent/PT3419595T/pt unknown
- 2017-02-24 KR KR1020187027128A patent/KR102756413B1/ko active Active
- 2017-02-24 HU HUE20202758A patent/HUE064432T2/hu unknown
- 2017-02-24 HR HRP20210367TT patent/HRP20210367T1/hr unknown
- 2017-02-24 AR ARP170100475A patent/AR107782A1/es not_active Application Discontinuation
- 2017-02-24 RS RS20210361A patent/RS61604B1/sr unknown
- 2017-02-24 DK DK17707527.2T patent/DK3419595T3/da active
- 2017-02-24 WO PCT/EP2017/054325 patent/WO2017144659A1/en not_active Ceased
- 2017-02-24 BR BR112018015166A patent/BR112018015166A2/pt active Search and Examination
- 2017-02-24 MA MA52595A patent/MA52595B1/fr unknown
- 2017-02-24 SI SI201730666T patent/SI3419595T1/sl unknown
- 2017-02-24 UA UAA201809497A patent/UA123107C2/uk unknown
- 2017-02-24 ES ES20202758T patent/ES2966262T3/es active Active
- 2017-02-24 LT LTEP17707527.2T patent/LT3419595T/lt unknown
- 2017-02-24 RS RS20231172A patent/RS64929B1/sr unknown
- 2017-02-24 MD MDE20190039T patent/MD3419595T2/ro unknown
- 2017-02-24 MX MX2018010201A patent/MX381709B/es unknown
- 2017-02-24 CN CN202110585922.3A patent/CN113398250B/zh active Active
- 2017-02-24 TN TNP/2018/000284A patent/TN2018000284A1/en unknown
- 2017-02-24 AU AU2017222292A patent/AU2017222292B2/en active Active
- 2017-02-24 PL PL17707527T patent/PL3419595T3/pl unknown
- 2017-02-24 EP EP20202758.7A patent/EP3791860B1/en active Active
- 2017-02-24 PL PL20202758.7T patent/PL3791860T3/pl unknown
- 2017-02-24 US US16/079,428 patent/US10792334B2/en active Active
- 2017-02-24 EP EP17707527.2A patent/EP3419595B1/en active Active
- 2017-02-24 MD MDE20210250T patent/MD3791860T2/ro unknown
- 2017-02-24 FI FIEP20202758.7T patent/FI3791860T3/fi active
- 2017-02-24 LT LTEP20202758.7T patent/LT3791860T/lt unknown
- 2017-02-24 HU HUE17707527A patent/HUE053492T2/hu unknown
- 2017-02-24 HR HRP20231477TT patent/HRP20231477T1/hr unknown
- 2017-02-24 CN CN201780013134.9A patent/CN108883061B/zh active Active
2018
- 2018-07-17 IL IL260626A patent/IL260626B2/en unknown
- 2018-07-23 CL CL2018001984A patent/CL2018001984A1/es unknown
- 2018-07-23 ZA ZA2018/04944A patent/ZA201804944B/en unknown
- 2018-07-27 CO CONC2018/0007810A patent/CO2018007810A2/es unknown
2020
- 2020-09-14 US US17/020,279 patent/US11666635B2/en active Active
2021
- 2021-08-18 JP JP2021133422A patent/JP2021191760A/ja active Pending
2022
- 2022-01-05 AU AU2022200027A patent/AU2022200027A1/en not_active Abandoned
2023
- 2023-04-21 US US18/138,000 patent/US12447196B2/en active Active
- 2023-09-15 JP JP2023150308A patent/JP2023164573A/ja active Pending
2025
- 2025-04-02 US US19/098,420 patent/US20250352621A1/en active Pending

Also Published As

Publication number	Publication date
HRP20231477T1 (hr)	2024-03-01
ES2966262T3 (es)	2024-04-19
KR102756413B1 (ko)	2025-01-16
EP4257149A2 (en)	2023-10-11
AU2022200027A1 (en)	2022-02-03
US11666635B2 (en)	2023-06-06
RS61604B1 (sr)	2021-04-29
EA201891905A1 (ru)	2019-02-28
PT3419595T (pt)	2021-03-29
CA3012759A1 (en)	2017-08-31
IL260626A (sr)	2018-09-20
US20210236600A1 (en)	2021-08-05
US10792334B2 (en)	2020-10-06
MA43686A (fr)	2019-01-02
MA43686B1 (fr)	2021-03-31
NZ744294A (en)	2024-08-30
TN2018000284A1 (en)	2020-01-16
TWI755377B (zh)	2022-02-21
WO2017144659A1 (en)	2017-08-31
MA52595A (fr)	2021-03-17
US20230372447A1 (en)	2023-11-23
LT3791860T (lt)	2023-12-11
DK3419595T3 (da)	2021-03-29
CN108883061B (zh)	2021-06-08
JP2021191760A (ja)	2021-12-16
IL260626B1 (en)	2023-04-01
JP2023164573A (ja)	2023-11-10
AR107782A1 (es)	2018-06-06
UA123107C2 (uk)	2021-02-17
MX2018010201A (es)	2019-06-06
EP3419595A1 (en)	2019-01-02
MD3791860T2 (ro)	2024-03-31
KR20180114178A (ko)	2018-10-17
SI3419595T1 (sl)	2021-04-30
PT3791860T (pt)	2023-12-15
LT3419595T (lt)	2021-03-10
DK3791860T5 (da)	2024-08-19
SI3791860T1 (sl)	2024-01-31
BR112018015166A2 (pt)	2018-12-18
CN113398250A (zh)	2021-09-17
US20250352621A1 (en)	2025-11-20
MA52595B1 (fr)	2023-12-29
PH12018501688B1 (en)	2023-08-02
CN108883061A (zh)	2018-11-23
AU2017222292A1 (en)	2018-07-26
RS64929B1 (sr)	2023-12-29
HUE053492T2 (hu)	2021-06-28
EP3419595B1 (en)	2021-01-06
HUE064432T2 (hu)	2024-03-28
GB201603280D0 (en)	2016-04-13
MX381709B (es)	2025-03-13
JOP20170046B1 (ar)	2021-08-17
EP4257149A3 (en)	2023-12-20
IL260626B2 (en)	2023-08-01
MD3419595T2 (ro)	2021-06-30
DK3791860T3 (da)	2023-12-18
EP3791860B1 (en)	2023-10-11
JP6932710B2 (ja)	2021-09-08
PL3791860T3 (pl)	2024-03-18
US12447196B2 (en)	2025-10-21
AU2017222292B2 (en)	2021-12-16
JP2019507153A (ja)	2019-03-14
CN113398250B (zh)	2024-02-23
MY193138A (en)	2022-09-26
PL3419595T3 (pl)	2021-06-14
FI3791860T3 (fi)	2024-01-11
CL2018001984A1 (es)	2018-09-14
TW201733612A (zh)	2017-10-01
US20190060409A1 (en)	2019-02-28
ZA201804944B (en)	2023-02-22
CO2018007810A2 (es)	2018-10-22
PH12018501688A1 (en)	2019-05-27
EA036383B1 (ru)	2020-11-03
HRP20210367T1 (hr)	2021-04-16
ES2862193T3 (es)	2021-10-07
EP3791860A1 (en)	2021-03-17

Publication	Publication Date	Title
SG11201806140SA (en)	2018-08-30	Stable liquid gonadotropin formulation
SG11201909949XA (en)	2019-11-28	Targeted immunotolerance
SG11201908330PA (en)	2019-10-30	Farnesoid x receptor agonists and uses thereof
SG11201909955XA (en)	2019-11-28	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201901206SA (en)	2019-04-29	Trimer stabilizing hiv envelope protein mutations
SG11201811230RA (en)	2019-01-30	Compositions and methods for reducing ocular neovascularization
SG11201809344QA (en)	2018-11-29	Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903514VA (en)	2019-05-30	Novel cd47 monoclonal antibodies and uses thereof
SG11201909825VA (en)	2019-11-28	Hsp90 inhibitor oral formulations and related methods
SG11201902531QA (en)	2019-05-30	Liquid pharmaceutical composition
SG11201808990QA (en)	2018-11-29	Compositions for topical application of compounds
SG11201804704PA (en)	2018-07-30	Compositions and methods for decreasing tau expression
SG11201809912UA (en)	2018-12-28	Hybrid carriers for nucleic acid cargo
SG11201807912SA (en)	2018-10-30	Vaccine against rsv
SG11201804729RA (en)	2018-07-30	Methods and compositions for treating a serpinc1-associated disorder
SG11201811442UA (en)	2019-01-30	Formulation of a peptide vaccine
SG11201408174UA (en)	2015-01-29	Antibody formulation
SG11201805001UA (en)	2018-07-30	Method of treating influenza a
SG11201900554YA (en)	2019-02-27	Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en)	2018-12-28	Spiro-lactam nmda receptor modulators and uses thereof
SG11201907023UA (en)	2019-08-27	Method of reducing neutropenia
SG11201809908TA (en)	2018-12-28	Stabilized glycopeptide antibiotic formulations
SG11201900558RA (en)	2019-02-27	Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en)	2019-02-27	Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en)	2019-02-27	Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof